UPCC 10518: An Open Label Single Arm Phase 1b/2 Study to Evaluate the Safety and Efficacy of Grapiprant (ARY-007) in Combination with Pembrolizumab in Patients with Advanced or Metastatic Post PD 1/L1 Non-Small Cell Lung Cancer (NSCLC) Adenocarcinoma
Enrolling By Invitation
99 years or below
All
Phase
2
10 participants needed
1 Location
Brief description of study
The primary purpose of this study is to gain information about the safety and activity of grapiprant when taken with pembrolizumab in patients who have actively growing or spreading type of advanced stage lung cancer called non-small cell lung cancer (NSCLC).
Eligibility of study
You may be eligible for this study if you meet the following criteria:
- Conditions: Non-small Cell Lung Cancer Adenocarcinoma
-
Age: 99 years or below
-
Gender: All
Updated on
04 Aug 2024.
Study ID: 831612
If you need assistance finding a non-cancer clinical research study or if you have any questions, please email psom-ocr@pobox.upenn.edu
For Cancer trials contact Penn Medicine's Cancer Trial Navigator at: PMCancerResearch@pennmedicine.upenn.edu or 215-349-8245
